Pembrolizumab plus axitinib combination and the paradigm change in the treatment of advanced renal cell carcinoma
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61989592%3A15110%2F20%3A73602249" target="_blank" >RIV/61989592:15110/20:73602249 - isvavai.cz</a>
Result on the web
<a href="https://www.futuremedicine.com/doi/abs/10.2217/fon-2020-0079" target="_blank" >https://www.futuremedicine.com/doi/abs/10.2217/fon-2020-0079</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.2217/fon-2020-0079" target="_blank" >10.2217/fon-2020-0079</a>
Alternative languages
Result language
angličtina
Original language name
Pembrolizumab plus axitinib combination and the paradigm change in the treatment of advanced renal cell carcinoma
Original language description
Sequential administration of single targeted agents has been challenged as the dominant treatment paradigm in patients with metastatic renal cell carcinoma by improved outcomes obtained with combination regimens based on immune checkpoint inhibitors. Most patients treated with sequential monotherapy eventually develop drug resistance and succumb to progressive disease, leading to the search for therapies that would overcome drug resistance and result in a more durable treatment response. Improved outcomes have been demonstrated in Phase 3 trials in comparison with sunitinib for the combinations of axitinib plus pembrolizumab, axitinib plus avelumab, bevacizumab plus atezolizumab and ipilimumab plus nivolumab. A statistically significant improvement of both progression-free and overall survival has been demonstrated for the axitinib plus pembrolizumab combination
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30204 - Oncology
Result continuities
Project
Result was created during the realization of more than one project. More information in the Projects tab.
Continuities
P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)
Others
Publication year
2020
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Future Oncology
ISSN
1479-6694
e-ISSN
—
Volume of the periodical
17
Issue of the periodical within the volume
3
Country of publishing house
GB - UNITED KINGDOM
Number of pages
14
Pages from-to
241-254
UT code for WoS article
000575132400001
EID of the result in the Scopus database
2-s2.0-85100014930